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Cardiac N-Terminal
Pro–B-Type Natriuretic
Peptide Assay
The assessment of cardiac
disease in dogs and cats can
be a challenging task.
Diagnostic techniques such as electrocardiography, radiography, and echocar-diography are relatively expensive, time-consuming, and in the case of car-diac ultrasound, require specialized equipment and expertise. Cardiac
N-terminal pro–B-type natriuretic peptide (NT-proBNP) is a blood-based assay
that can assist practitioners in detection of underlying heart disease and differen-
tiation of cardiac versus noncardiac etiology of respiratory signs.
The physiology of NT-proBNP is intriguing. In addition to its pump function,
the heart is also an endocrine organ, and natriuretic peptides, such as B-type
natriuretic peptide (BNP), are secreted by atrial and ventricular myocytes prima-
rily in response to dilation or stretch.1,2 Cardiac NT-proBNP is a byproduct of
BNP production (Figure 1). The biologic actions of BNP are counter to those of
the renin-angiotensin-aldosterone system. That is, BNP elicits vasodilation, natri-
uresis, and diuresis.
Cardiac disease, including degenerative mitral valve disease, dilated cardiomyopa-
thy, and hypertrophic cardiomyopathy, is associated with elevated production of
BNP and, therefore, elevated formation of NT-proBNP.3-8 NT-proBNP is more
stable in circulation than BNP and can be detected using standard ELISA-based
technology. NT-proBNP is formed in a 1:1 ratio with BNP and can be used to
help detect heart disease and determine etiology of respiratory signs in both dogs
and cats.3-11
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Schematic of NT-proBNP secretion
and release. Note that the biologi-
cally active hormone is actually BNP,
and NT-proBNP is a byproduct of its
formation. Due to NT-proBNP’s
greater stability in circulation, the
diagnostic assay tests for the NT-
proBNP molecule as opposed to BNP
itself. This method is valid because
NT-proBNP is produced in a 1:1 fash-
ion with BNP.
BNP = B-type natriuretic peptide; ELISA = enzyme-linked immunosorbent assay; NT-proBNP = N-terminal
pro–B-type natriuretic peptide
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Heart Disease in Dogs
Dogs with degenerative mitral valve disease or
dilated cardiomyopathy generally have elevated
plasma NT-proBNP levels. It is important to
note that in older, small-breed dogs with no
clinical signs, the diagnosis of mitral valve dis-
ease is easily made by auscultation.
Participate in an online study designed
to test and improve your cardiac
diagnostic skills.
The purpose of this study is to
determine veterinarians’ accuracy when
diagnosing congestive heart failure
(CHF) or primary pulmonary disease as
the etiology of respiratory signs in dogs.
The hypothesis is that NT-proBNP assay
will help improve accuracy of diagnosis
and veterinarian confidence when used
in conjunction with traditional diagnos-
tics, such as electrocardiography and
thoracic radiography.
The survey contains actual case data
from dogs and cats that presented for
evaluation of respiratory signs to 1 of 2
veterinary referral centers (University
of Pennsylvania and Tufts University).
Based on your evaluation of the diagnos-
tic tests, you will determine a diagnosis
of CHF or primary respiratory disease
before and after disclosure of the
NT-proBNP results.
To obtain more information about the
study and to earn continuing education
credit, visit vetmedce.org.
DIAGNOSTIC INDICATIONS
The differentiation of congestive heart failure
from primary respiratory disease in animals that
present with respiratory signs, such as coughing,
wheezing, increased respiratory effort, or emer-
gent respiratory distress, can be challenging.
NT-proBNP is released in response to myocar-
dial stretch and consequently is typically ele-
vated in animals with congestive heart failure.
As a result, markedly elevated NT-proBNP at
time of presentation may help alert practitioners
to a high likelihood of heart failure (as opposed
to primary respiratory disease) as the cause of
clinical signs.
Heart Disease in Cats
The most common acquired heart diseases in
cats are hypertrophic and restrictive cardiomy-
opathy. These diseases present a unique diagnos-
tic challenge because many cats with significant
disease have no clinical signs for long periods of
time. Moreover, physical examination findings
(including heart murmurs and gallops), which
are suggestive of underlying disease, can be dif-
ficult to detect in many animals.
Cats with plasma levels of NT-proBNP < 100
pmol/L are unlikely to be affected by clinically
significant heart disease. In patients with mild
elevations of plasma NT-proBNP levels (100
–270 pmol/L), further diagnostics, such as
echocardiography, are recommended if the clini-
cal suspicion of heart disease is high. Plasma
NT-proBNP levels > 270 pmol/L indicate a
high likelihood of underlying heart disease; fur-
ther workup is recommended.
False-positives and false-negatives can occur and
results of NT-proBNP assays should be inter-
preted in conjunction with history, physical
examination findings, and other diagnostic tests.
Most important, NT-proBNP testing reflects
current heart function, and a single normal
result does not preclude the possibility of disease
development at a future date. Therefore, NT-
proBNP testing is not recommended as a
screening tool in young cats of breeding age.
There is a $35 fee per CE credit (assessed by the University of
Wisconsin CE program); participants can take up to 3 CE credits.
The survey is free for participants not receiving CE credit.
Participate
in a Series of Case Studies
Test & Improve Your
Cardiac Diagnostic Skills
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The severity of heart disease as assessed by clin-
ical signs and heart size is moderately correlated
to the degree of NT-proBNP elevation. Dogs
with plasma NT-proBNP levels < 900 pmol/L
are very unlikely to be affected by clinically sig-
nificant heart disease. If a dog has mildly ele-
vated concentrations of plasma NT-proBNP
levels (900–1800 pmol/L) and the clinical pres-
entation is suspicious for heart disease, further
workup, including thoracic radiographs or
echocardiography, is recommended. Plasma NT-
proBNP levels > 1800 pmol/L are severely ele-
vated and the likelihood of heart failure is high
if clinical signs are present.
False-positives and false-negatives can occur and
results of NT-proBNP assays should be inter-
preted in conjunction with history, physical
examination findings, and other diagnostic tests.
Current diagnostic recommendations for dogs
and cats are summarized in the Table.
PROGNOSTIC INDICATIONS
An intriguing use of NT-proBNP assay involves
assessment of morbidity and mortality risk in
dogs with mitral valve disease. A recent study
reported that dogs with higher NT-proBNP
values had a greater risk of death due to cardiac
causes than dogs with lower values.12 This find-
ing, along with those of others,13 suggests that
NT-proBNP assay may identify subpopulations
of dogs that would benefit from closer monitor-
ing or more aggressive therapy. Future clinical
trials should help clarify the role of NT-proBNP
in identifying risk and guiding therapy in dogs
with mitral valve disease.
ADVANTAGES
The advantages of blood-based testing for dis-
ease are self-evident. The ease, rapidity, cost,
widespread availability, and objective results are
highly attractive (Figure 2). NT-proBNP assay
appears to provide objective and prognostic data
that is independent of conventional testing.
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By virtue of its blood-based
characteristics, NT-proBNP
assay is relatively affordable
and easy to perform.
NT-proBNP = N-terminal pro–B-type natriuretic peptide
Table.
NT-proBNP as a Diagnostic Tool for Heart Disease
NT-proBNP Plasma Level Indication
Cats
‹ 100 pmol/L Clinically significant heart disease
unlikely
100–270 pmol/L Further diagnostics recommended if
clinical suspicion of heart disease is
high
› 270 pmol/L High likelihood of underlying heart
disease; further workup recommended
Dogs
‹ 900 pmol/L Clinically significant heart disease
unlikely
900–1800 pmol/L Further diagnostics recommended if
clinical suspicion of heart disease is
high
› 1800 pmol/L High likelihood of heart failure if
clinical signs are present
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DISADVANTAGES
As with any diagnostic test, the results of NT-
proBNP assays should not be interpreted in iso-
lation. This assay should be used in conjunction
with signalment, history, physical examination
findings, and, if indicated, other diagnostic
tests, such as radiography, echocardiography,
electrocardiography, blood pressure measure-
ment, serum biochemistry, and thyroid assay. It
is important to note that concurrent renal dis-
ease or prerenal azotemia causes elevations in
NT-proBNP in both dogs and cats; in these
instances values should be interpreted cau-
tiously.
The clinical value of a diagnostic test is framed
by a competing balance between sensitivity and
specificity (Figure 3). While a completely
dichotomous test (one that definitively says
either “yes” or “no”) would be the most desirous,
NT-proBNP, like many other blood-based
assays, produces a continuum of results, includ-
ing normal, moderately elevated, and severely
elevated values. Both false-positive and false-
negative results can exist, especially in animals
with relatively mild disease7,14 or animals with
concurrent heart and respiratory ailments.9-11
Currently, the NT-proBNP assay is only avail-
able as a “send-out” assay and reporting of
results requires approximately 24 hrs. This limits
the utility of the assay in the emergent patient
where rapid clinical decision making and treat-
ment is desired.
ECONOMIC IMPACT
Blood-based assays are generally much less
expensive than other diagnostic tests, such as
thoracic radiography and echocardiography.
Clinicians may find that performing a NT-
proBNP assay improves confidence and owner
compliance when deciding if more expensive
diagnostics should or should not be pursued.
The NT-proBNP assay represents a new para-
digm for the assessment of cardiac disease in
veterinary medicine, and as such, clinicians
should realize that additional data are needed to
completely understand the role of cardiac blood-
based testing. A variety of studies addressing
many important issues are underway.
See Aids & Resources, back page, for references
and suggested reading.
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The clinical value of a diagnostic
test is a balance between sensitivity
and specificity. The challenge is to
find assays that maximize each of
these parameters.
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